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The development of centres of expertise (CE) and
European Reference Networks (ERN) in the field of rare
diseases (RD) is encouraged in the Council Recommen-
dation on an Action in the Field of RD (2009/C 151/02)
(8 June 2009) and most recently in the Directive on the
application of patients’ rights in cross-border healthcare
(2011/24/EU) (9 March 2011) as a means of organising
care for thousands of heterogeneous RD affecting scat-
tered patient populations across Europe. The European
Union Committee of Experts on Rare Diseases (EUCERD
http://www.eucerd.eu) issued a set of Recommendations
on Quality Criteria for Centres of Expertise for Rare Dis-
eases in Member States [1] to guide Member States (MS)
in this area.
The scope of CE in terms of disease coverage is an
important issue as the expectation is to provide CE for all
RD patients’ needs at national level. Denmark, France,
Norway, Spain and the UK, for example, have already
identified existing expertise at national level and/or
established centres specialised in some RD/groups of RD
which have proven to be very efficient in improving qual-
ity of care. The Scientific Secretariat of the EUCERD
examined the current scope of CE in countries where
they exist. CE were grouped by medical area. Three or
more MS have designated centres for: juvenile arthritis/
paediatric rheumatological diseases, developmental
anomalies and malformations/dysmorphology, hereditary
cardiac diseases, dermatological diseases, epidermolysis
bullosa, pituitary diseases or hypothalamic-hypophyseal
diseases, lysosomal diseases, Prader-Willi syndrome,
Fabry disease, mitochondrial diseases, haemophilia/con-
stitutional bleeding disorders, mastocytosis, hereditary
diseases of the metabolism, porphyrias, epilepsies,
neuromuscular diseases, amyotrophic lateral sclerosis,
pulmonary diseases, severe pulmonary hypertension, cys-
tic fibrosis, hereditary immune deficiencies, opthalmolo-
gical diseases, genetic kidney disease, cranofacial
anomalies, neurofibromatosis, Rendu-Osler disease.
On the basis of this experience, a consensus can be thus
identified that centres are required for around 12 groups of
RD, 30 subgroups, and 26 individual diseases where centres
currently exist in two or more countries. Most of these
groups of RD fit into the traditional organisation of health-
care by medical area. However some grouping outside of
traditional medical specialities is necessary, e.g. diseases of
connective tissue, rare bone diseases, neurofibromatosis,
multimalformation syndromes with intellectual disability,
mitochondrial diseases, lysosomal diseases, any multi-
systemic complex disease, etc. This analysis could be of use
for MS currently considering the organisation of CE for RD.
This work was carried out by the EUCERD Scientific
Secretariat with the support of EC Joint Action N°
20082291.
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